United Therapeutics Corp
NASDAQ:
UTHR
-
United Therapeutics Corp
-
Sector
Health Care
-
Industry
Biotechnology
-
Company web
Link
-
Employees
Full Time Employees: 750
-
Executives
- Martine Rothblatt
- Michael Benkowitz
- Christopher Patusky
- James Edgemond
- Paul Mahon
- Raymond Dwek
- Christopher Causey
- Richard Giltner
- Katherine Klein
- Raymond Kurzweil
-
Company address
- 1040 Spring Street
- Silver Spring, MD 20910
- United States of America
- 1-301-608-9292
-
Investor Relation Site
Link
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corp: Slide deck
- UTHR-FORM 10-K For the fiscal year ended December 31, 2016: Slides deck